Home / Companies / Glenmark Pharmaceuticals Limited / 27 Sep 2024
Glenmark Pharmaceuticals Limited: meeting of 27 Sep 2024
Votes reported on Form N-PX, item by item
42 Form N-PX filers reported votes at the Glenmark Pharmaceuticals Limited meeting of 27 Sep 2024. Their records fall into 6 items below, in ballot order: management items first, then proposals from security holders. Each bar shows how the reporting filers split; it is not the result of the meeting.
foragainstabstain, withhold or otheramber tick: the portion cast against management
Items
DIRECTOR ELECTIONSIssuer
Director elections
1 nominee; 75.4% of reported votes for; 9 filers withheld from or voted against at least one nominee.
57 vote records from 42 filers. 9 of the 42 filers that marked the item either way voted against management.
AUDIT-RELATEDIssuer
Audit-related items (auditor ratification)
16 vote records from 11 filers. 0 of the 11 filers that marked the item either way voted against management.
CAPITAL STRUCTUREIssuer
CAPITAL STRUCTURE: management items
Management items in this category are shown together; filers word and number them differently.
57 vote records from 42 filers. 0 of the 42 filers that marked the item either way voted against management.
COMPENSATIONIssuer
COMPENSATION: management items
Management items in this category are shown together; filers word and number them differently.
43 vote records from 31 filers. 0 of the 31 filers that marked the item either way voted against management.
CORPORATE GOVERNANCEIssuer
CORPORATE GOVERNANCE: management items
Management items in this category are shown together; filers word and number them differently.
104 vote records from 37 filers. 0 of the 37 filers that marked the item either way voted against management.
OTHERIssuer
OTHER: management items
Management items in this category are shown together; filers word and number them differently.
8 vote records from 4 filers. 0 of the 4 filers that marked the item either way voted against management.
How the largest families voted
| Family | 1. Directors | 2. Auditor |
|---|---|---|
| Vanguard | For | No report |
| BlackRock and iShares | For | For |
| Fidelity | For | No report |
| Dimensional | For | No report |
| State Street and SPDR | For | No report |
| American Century | Against * | No report |
| Franklin Templeton | For | No report |
| Invesco | Against * | No report |
| Charles Schwab | Against * | For |
| Nuveen and TIAA | Against * | No report |
| John Hancock and Manulife | For | For |
| Morgan Stanley, Eaton Vance and Calvert | Against * | No report |
| J.P. Morgan | Against * | For |
| Goldman Sachs | For | No report |
| WisdomTree | For | No report |
| Jackson National funds | For | For |
| Northern Trust and FlexShares | For | No report |
| Nationwide | For | No report |
| Victory Capital | For | No report |
| Brighthouse Funds | For | No report |
| Capital Group and American Funds | For | No report |
| Hartford Funds | Against * | For |
| PIMCO | Against * | No report |
| Macquarie and Delaware Funds | For | No report |
* against management. A family's position is the way most of its reported shares were voted across its filers; "split" means no single position led. "No report" means none of the family's filers listed the item.
Questions
How did large funds vote at the Glenmark Pharmaceuticals Limited meeting?
42 Form N-PX filers reported votes at the meeting of 27 Sep 2024. The family table lists each of the largest families item by item.
Is this the meeting result?
No. These are the votes of funds and managers that file Form N-PX, counted by filer and by the shares they reported. The certified result, which includes every shareholder, is reported by Glenmark Pharmaceuticals Limited on Form 8-K.
Why are director elections shown as counts only?
Director records name the nominee. This site does not publish pages or rows about individuals, so for director elections it keeps the number of nominees and the split of votes and discards the wording.
Every meeting on file for Glenmark Pharmaceuticals Limited
Provenance: SEC EDGAR, Form N-PX and N-PX/A filings listing Glenmark Pharmaceuticals Limited with a meeting date within three days of 27 Sep 2024. Proposal titles are the most common wording among filers and are replaced by the SEC category where a wording could name a person. Not verified by the SEC. Filings read through 23 Sep 2026.